Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Georg Lenz(Charité - Universitätsmedizin Berlin), Louis M. Staudt(National Cancer Institute), N. C. Tolga Emre(National Institutes of Health), Wing C. Chan(Ontario Institute for Cancer Research), Dennis D. Weisenburger(University of Nebraska Medical Center), Joseph M. Connors, Andreas Rosenwald(Comprehensive Cancer Center Mainfranken), Elı́as Campo(Hospital Clínic de Barcelona), Randy D. Gascoyne(BC Cancer Agency), Lloyd T. Lam(National Institutes of Health), John Powell(National Institutes of Health), R. Eric Davis(The University of Texas MD Anderson Cancer Center), Holger Kohlhammer(Max Planck Institute for Metabolism Research), Shannon A. Carty(National Institutes of Health), German Ott(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Wenming Xiao(World Wide Web Consortium), Jan Delabie, George W. Wright(National Cancer Institute), Sandeep S. Davé(Duke University), Elaine S. Jaffe(National Cancer Institute), Richard I. Fisher(University of Rochester), Hans Konrad Müller‐Hermelink(University of Würzburg), Arthur L. Shaffer(World Wide Web Consortium), Erlend B. Smeland(Norwegian Cancer Society), Lisa M. Rimsza(Banner - University Medical Center Tucson)
Cited by 985
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k